RT Journal Article
T1 Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19.
A1 Lavilla Olleros, Cristina
A1 Ausín García, Cristina
A1 Bendala Estrada, Alejandro David
A1 Muñoz, Ana
A1 Wikman Jogersen, Philip Erick
A1 Fernández Cruz, Ana
A1 Giner Galvañ, Vicente
A1 Vargas, Juan Antonio
A1 Seguí Ripoll, José Miguel
A1 Rubio-Rivas, Manuel
A1 Miranda Godoy, Rodrigo
A1 Mérida Rodrigo, Luis
A1 Fonseca Aizpuru, Eva
A1 Arnalich Fernández, Francisco
A1 Artero, Arturo
A1 Loureiro Amigo, Jose
A1 García García, Gema María
A1 Corral Gudino, Luis
A1 Jiménez Torres, Jose
A1 Casas-Rojo, José-Manuel
A1 Millán Núñez-Cortés, Jesús
A1 SEMI-COVID-19 Network, 
AB To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p  There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses.
YR 2022
FD 2022-01-21
LK http://hdl.handle.net/10668/20414
UL http://hdl.handle.net/10668/20414
LA en
DS RISalud
RD Apr 17, 2025